Cytokeratin 18 (CK18) is a type I intermediate filament protein that, together with its type II partner cytokeratin 8 (CK8), forms structural keratin filaments in the cytoplasm of epithelial cells. These filaments are essential for maintaining mechanical stability and resilience of simple epithelial tissues throughout the body, including the gastrointestinal (GI) tract. CK18 has also been implicated in key cellular processes such as apoptosis, cell cycle progression, and signaling pathways relevant to cancer biology.
Biological Significance of Cytokeratin 18
Because CK18 is a fundamental structural protein of epithelial cells, changes in its expression patterns can reflect underlying alterations in cellular differentiation or malignant transformation. For example, CK18 may be downregulated in cancers that originate from tissues that normally express CK18, or it may be aberrantly upregulated in tumor types where it is not typically found. These shifts are sometimes linked to tumor progression, grade, and metastatic potential.
Diagnostic Utility in Gastrointestinal Pathology
In diagnostic surgical pathology, immunohistochemistry (IHC) is indispensable for characterizing tissue origin, especially in poorly differentiated neoplasms or metastatic disease involving the GI tract. CK18 immunostaining helps to confirm epithelial differentiation and to distinguish adenocarcinomas of GI origin from other tumor types with similar morphology. This is especially useful in gastrointestinal adenocarcinomas, where CK18 expression is typically near-universal and can support identification of epithelial origin in metastatic biopsies.
In addition to tissue IHC, CK18 fragments (total and caspase-cleaved forms) detectable in serum have been explored as non-invasive biomarkers in digestive cancers. Meta-analyses suggest that levels of circulating CK18 fragments correlate with prognosis in patients with GI malignancies, reflecting tumor burden and cell death dynamics.
Key Features of Anti-Cytokeratin 18 CE/IVD Antibodies
Anti-CK18 antibodies validated for CE/IVD (In Vitro Diagnostic) use for IHC are designed to reliably bind CK18 epitopes within formalin-fixed, paraffin-embedded (FFPE) tissue sections. Key features that researchers and clinical pathologists seek in such reagents include:
- High specificity for CK18 protein, minimizing cross-reactivity with non-target proteins and reducing false positives in epithelial and carcinoma profiling.
- Strong sensitivity in diagnostic contexts, enabling consistent visualization of CK18 expression across a range of GI tumor subtypes, particularly adenocarcinomas.
- Reproducibility under standardized protocols, essential for CE/IVD compliance and for integration into routine histopathology workflows.
- Compatibility with automated IHC platforms widely used in clinical and research laboratories.
The use of standardized anti-CK18 IHC reagents supports accurate tumor classification, assists in differential diagnosis, and enhances the interpretative confidence of histopathologists investigating GI pathology specimens.
